3-(4-OXO-6-PHENYL-1,4-DIHYDRO-PYRIMIDIN-2-YLSULFANYL)-PROPIONIC ACID
|
- $200 - $874
- Product name: 3-(4-OXO-6-PHENYL-1,4-DIHYDRO-PYRIMIDIN-2-YLSULFANYL)-PROPIONIC ACID
- CAS: 333413-05-1
- MF: C13H12N2O3S
- MW: 276.31
- EINECS:
- MDL Number:MFCD02734327
- Synonyms:TOSLAB 803371;3-(4-OXO-6-PHENYL-1,4-DIHYDRO-PYRIMIDIN-2-YLSULFANYL)-PROPIONIC ACID;3-[(4-OXO-6-PHENYL-1,4-DIHYDROPYRIMIDIN-2-YL)THIO]PROPANOIC ACID;3-((4-Hydroxy-6-phenylpyrimidin-2-yl)thio)propanoic acid;Propanoic acid, 3-[(1,6-dihydro-6-oxo-4-phenyl-2-pyrimidinyl)thio]-
3 prices
Selected condition：
Brand
- Crysdot
- Matrix Scientific
Package
- 500mg
- 1g
- 5g
- ManufacturerCrysdot
- Product numberCD11142315
- Product description3-((4-Oxo-6-phenyl-1,4-dihydropyrimidin-2-yl)thio)propanoicacid 97%
- Packaging5g
- Price$874
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number011909
- Product description3-(4-Oxo-6-phenyl-1,4-dihydro-pyrimidin-2-ylsulfanyl)-propionic acid
- Packaging1g
- Price$308
- Updated2021-12-16
- Buy
- ManufacturerMatrix Scientific
- Product number011909
- Product description3-(4-Oxo-6-phenyl-1,4-dihydro-pyrimidin-2-ylsulfanyl)-propionic acid
- Packaging500mg
- Price$200
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Crysdot | CD11142315 | 3-((4-Oxo-6-phenyl-1,4-dihydropyrimidin-2-yl)thio)propanoicacid 97% | 5g | $874 | 2021-12-16 | Buy |
| Matrix Scientific | 011909 | 3-(4-Oxo-6-phenyl-1,4-dihydro-pyrimidin-2-ylsulfanyl)-propionic acid | 1g | $308 | 2021-12-16 | Buy |
| Matrix Scientific | 011909 | 3-(4-Oxo-6-phenyl-1,4-dihydro-pyrimidin-2-ylsulfanyl)-propionic acid | 500mg | $200 | 2021-12-16 | Buy |
Properties
Boiling point :505.3±60.0 °C(Predicted)
Density :1.37±0.1 g/cm3(Predicted)
pka :4.03±0.10(Predicted)
Density :1.37±0.1 g/cm3(Predicted)
pka :4.03±0.10(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|